Celcuity jumps as traders position for July 17 PDUFA and Q2 Phase 3 data
Celcuity shares rose as investors refocused on near-term regulatory and data catalysts for its breast-cancer drug candidate gedatolisib. The FDA has accepted Celcuity’s NDA and granted Priority Review with a July 17, 2026 PDUFA goal date, and the company expects topline Phase 3 VIKTORIA-1 PIK3CA-mutant cohort results in Q2 2026.
1. What’s moving the stock
Celcuity (CELC) is higher as the market leans into a catalyst-driven setup in oncology, with attention on the company’s regulatory timeline for gedatolisib and a pending Phase 3 data release. Celcuity has said the FDA accepted its New Drug Application and granted Priority Review, setting a July 17, 2026 PDUFA goal date for gedatolisib in HR+/HER2-/PIK3CA wild-type advanced breast cancer, while separate topline results from the Phase 3 VIKTORIA-1 PIK3CA-mutant cohort are expected in the second quarter of 2026. (ir.celcuity.com)
2. The catalyst calendar investors are watching
The next major binary event on the calendar is the FDA action date on July 17, 2026, which would determine whether gedatolisib can move toward commercialization in the specified advanced breast cancer setting. Ahead of that decision, Celcuity has guided to a Q2 2026 topline readout from the VIKTORIA-1 PIK3CA-mutant cohort, a release that could influence expectations for label breadth and commercial potential. (ir.celcuity.com)
3. Why the move can happen without fresh headlines
In biotech, shares can move on days with no new press release as traders rebalance around defined milestones and potential information flow, particularly when a company has a known FDA decision date and a near-term Phase 3 readout window. Celcuity’s March 25, 2026 corporate update reiterated both the Priority Review/PDUFA date and the expected Q2 2026 mutant-cohort data timing, giving the market clear reference points that can drive positioning. (ir.celcuity.com)
4. What to watch next
Key near-term watch items include any FDA review updates, label-related signals, or manufacturing/commercial-readiness commentary as July approaches, plus the exact timing and details of the VIKTORIA-1 PIK3CA-mutant cohort topline release within Q2 2026. Investors will also be monitoring cash burn and any financing signals as Celcuity prepares for a potential U.S. launch timeline tied to the July 17, 2026 decision date. (ir.celcuity.com)